INmune Bio (INMB) Projected to Post Earnings on Monday

INmune Bio (NASDAQ:INMB) is anticipated to announce its Q4 2025 results before the market opens on Monday, March 9th. Analysts expect INmune Bio to post earnings of ($0.28) per share for the quarter. Parties are encouraged to explore the company’s upcoming Q4 2025 earning overview page for the latest details on the call scheduled for Friday, March 27, 2026 at 4:00 PM ET.

INmune Bio Stock Performance

INMB stock opened at $1.33 on Friday. The business has a 50-day simple moving average of $1.51 and a two-hundred day simple moving average of $1.74. The company has a market capitalization of $35.35 million, a P/E ratio of -0.63 and a beta of 0.77. INmune Bio has a 52-week low of $1.21 and a 52-week high of $11.64.

Hedge Funds Weigh In On INmune Bio

Several institutional investors have recently bought and sold shares of the company. Virtu Financial LLC bought a new position in shares of INmune Bio during the 4th quarter worth $32,000. XTX Topco Ltd lifted its stake in shares of INmune Bio by 41.3% during the 4th quarter. XTX Topco Ltd now owns 68,865 shares of the company’s stock valued at $107,000 after buying an additional 20,121 shares in the last quarter. Quadrature Capital Ltd purchased a new stake in shares of INmune Bio during the 4th quarter valued at approximately $26,000. Jain Global LLC bought a new position in INmune Bio in the 4th quarter worth approximately $66,000. Finally, Charles Schwab Investment Management Inc. boosted its holdings in INmune Bio by 20.1% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 50,252 shares of the company’s stock worth $78,000 after buying an additional 8,427 shares during the period. Hedge funds and other institutional investors own 12.72% of the company’s stock.

Wall Street Analysts Forecast Growth

Separately, Wall Street Zen upgraded INmune Bio from a “sell” rating to a “hold” rating in a report on Saturday, February 28th. One analyst has rated the stock with a Buy rating, two have assigned a Hold rating and two have given a Sell rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Reduce” and a consensus target price of $8.00.

INmune Bio Company Profile

INmune Bio, Inc is a clinical-stage immunology company based in San Diego, California, focused on harnessing the innate immune system to combat a range of serious diseases. The company’s research and development efforts concentrate on modulating cellular pathways to restore and enhance the body’s natural defenses, particularly in oncology and neurodegenerative conditions.

The company’s lead therapeutic candidate, XPro1595 (also referred to as INB03), is a proprietary selective inhibitor of soluble tumor necrosis factor (TNF) designed to reduce chronic inflammation without impairing membrane-bound TNF functions.